Midsummer Capital is a private investment firm that manages hedge funds as well as provides advisory services
MidOcean Partners is a premier alternative asset manager that specializes in middle market private equity and alternative credit investments. Since inception, the focus of MidOcean Private Equity has been on high-quality middle market companies with attractive strategic, operational and financial growth opportunities in the consumer and business services sectors
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
---|---|---|---|---|
Sep 1, 2014
Kwanji
|
Seed | £450K | B2B | — |
Nov 25, 2013
Kwanji
|
Seed | £300K | B2B | — |
Mar 29, 2010
Sevion Therapeutics
|
Post-IPO Equity | $11.50M | Biopharma | — |
Aug 20, 2009
CEL-SCI
|
Post-IPO Equity | $4.40M | Biotechnology | — |
Midsummer Capital has had 2 exits. Midsummer Capital most notable exits include Sevion Therapeutics , CEL-SCI
Date | Company Name | Exit Type | Industry | |
---|---|---|---|---|
Jan 14, 2000 | Sevion Therapeutics | M&A | Biopharma | Detail |
Dec 9, 1983 | CEL-SCI | IPO | Biotechnology | Detail |